Research Article
Volume 9 Issue 12 - 2020
Long Term Effect of Denosumab on Densitometry Evolution in Women Patients
Gonzalez Lissette Alejandra* and Rodriguez MA
HM Hospitalez, Spain
*Corresponding Author: Gonzalez Lissette Alejandra, HM Hospitalez, Spain.
Received: July 14, 2020; Published: November 30, 2020


Introduction: Osteoporosis is one of the most common bone disease in the world. The side effect associate to bone fractures increases the morbidity and mortality especially in aging women.

Recently, a monoclonal antibody directed against activator nuclear factor k B ligand receptor (RANKL) denominated Denosumab has been approved as an initial therapy for bone fracture high risk patients (e.g. aging, bisphosphonates intolerant or contraindicated).

Denosumab exert their effect inhibiting the osteoclasts function and decreasing the bone resorption. Several studies have demonstrated that Denosumab increased dual-energy X-ray absorptiometry (DXA) areal bone mineral density (aBMD) and decreased the bone turnover as well as the risk of new vertebral, non-vertebral, and hip fractures. However, the level of response to treatment with Denosumab among patients with or without osteoporosis in a long term evaluated by densitometry is unknown. The aim of this study is (a) to identify the proportion of women that decrease the bone density after starting the Denosumab treatment and (b) to identify factors associate to the decreasing bone density in women receiving Denosumab.

Materials and Methods: This retrospective, unicenter and real world study was conducted in the Gynaecology Unit of HM Hospitals during January 2013 to December 2015. Inclusion criteria: women older than 40 years old medicated with denosumab and with two consecutives densitometries.

T0 include all variables and the densitometry result immediately before the Denosumab treatment was prescribed. Then densitometries were routinely performed at 2 - 3 years, at 4 - 5 years and 6 - 7 years from treatment prescription. Treatment failure was considered when the second densitometry was lower than 2.7% regarding the previous.

Results: During the study period 834 patients have received Denosumab; The final sample included 365 patients of which 123 patients (33,6%) not reduce more than 2.7% at any time compared to the previous densitometry, (considering no decrease at the femoral or lumbar level).

When analyzing each one of the variables with its association to the failure of the treatment with Denosumab, none of the variables allows to predict which patient will respond or not to the treatment.

Conclusion: More studies are needed to validate these results and find other factors that may influence the response to Denosumab during long-term treatment and also assess the risk of fractures in patients who do not respond adequately to treatment.

Keywords: Osteoporosis; RANKL; Dual-Energy X-Ray Absorptiometry (DXA); Areal Bone Mineral Density (aBMD)


  1. Braithwaite RS., et al. “Estimating hip fracture morbidity, mortality and costs”. Journal of the American Geriatrics Society3 (2003): 364-370.
  2. Johnell O and Kanis JA. “An estimate of the worldwide prevalence and disability associated with osteoporotic fractures”. Osteoporosis International: A Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 12 (2006): 1726-1733.
  3. Tella SH and Gallagher JC. “Prevention and treatment of postmenopausal osteoporosis”. The Journal of Steroid Biochemistry and Molecular Biology 142 (2014): 155-170.
  4. Cosman F. “Long-term treatment strategies for postmenopausal osteoporosis”. Current Opinion in Rheumatology4 (2018): 420-426.
  5. Moro Alvarez MJ., et al. “[Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates]”. Medicina Clinica1 (2016): 24-29.
  6. Khosla S. “Increasing options for the treatment of osteoporosis”. The New England Journal of Medicine8 (2009): 818-820.
  7. Cummings SR., et al. “Denosumab for prevention of fractures in postmenopausal women with osteoporosis”. The New England Journal of Medicine8 (2009): 756-765.
  8. Jamal SA., et al. “Effects of denosumab on fracture and bone mineral density by level of kidney function”. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 8 (2011): 1829-1835.
  9. McClung MR., et al. “Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis”. Journal of Clinical Densitometry: the Official Journal of the International Society for Clinical Densitometry 2 (2013): 250-256.
  10. Papapoulos S., et al. “The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study”. Osteoporosis International: A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 12 (2015): 2773-2783.
  11. Bone HG., et al. “10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension”. The lancet Diabetes and Endocrinology7 (2017): 513-523.
  12. Costa AG and Bilezikian JP. “How Long to Treat with Denosumab”. Current Osteoporosis Reports6 (2015): 415-420.
  13. Iseri K., et al. “Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: A randomized, controlled trial”. Journal of Bone and Mineral Research: the official journal of the American Society for Bone and Mineral Research6 (2019): 1014-1024.
  14. Cummings SR., et al. “Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis”. Journal of bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research1 (2017): 3-10.
  15. Obermayer-Pietsch B and Schwetz V. “[Biochemical markers of bone metabolism and their importance]”. Zeitschrift fur Rheumatologie5 (2016): 451-458.
  16. Tsourdi E., et al. “Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS”. Bone 105 (2017): 11-17.
  17. Rizzoli R. “Postmenopausal osteoporosis: Assessment and management”. Best Practice and Research Clinical Endocrinology and Metabolism5 (2018): 739-757.
  18. Compston J., et al. “UK clinical guideline for the prevention and treatment of osteoporosis”. Archives of Osteoporosis1 (2017): 43.
  19. Chen CL., et al. “Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass”. The Journal of Clinical Endocrinology and Metabolism (2015): 2784-2792.
Citation: Gonzalez Lissette Alejandra and Rodriguez MA. “Long Term Effect of Denosumab on Densitometry Evolution in Women Patients”. EC Gynaecology 9.12 (2020): 67-73.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

October Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the October issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before October 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to